Search
Prostaglandin G2
go.drugbank.com/drugs/DB03866ExperimentalA cyclic endoperoxide intermediate produced by the action of CYCLOOXYGENASE on ARACHIDONIC ACID. It is further converted by a series of specific enzymes to the series 2 prostaglandins. [PubChem]
Otelixizumab
go.drugbank.com/drugs/DB05496InvestigationalOtelixizumab is a monoclonal antibody that binds to a receptor found on all T cells called CD3, which is involved in normal T cell signaling. … Otelixizumab is believed to inhibit the function of autoreactive T cells, which are important in propagating autoimmune diseases, while inducing regulatory T cell pathways that promote immunological tolerance
PN0621
go.drugbank.com/drugs/DB05218ExperimentalPN0621 is an anti-TNF, domain antibody (dAb) based therapeutic. It targets tumour necrosis factor (TNF) to treat auto-immune inflammatory diseases such as rheumatoid arthritis. … It is being developed by Peptech.
BMS-986141
go.drugbank.com/drugs/DB14942InvestigationalBMS-986141 is under investigation in clinical trial NCT02985632 (A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants).
Categories: Heterocyclic Compounds, 1-RingLumiliximab
go.drugbank.com/drugs/DB06162InvestigationalIt is a primatized anti-CD23 macaque/human chimeric antibody that inhibits the production of the IgE antibody, for the potential treatment of allergic conditions. … Results published from the CLL clinical trial failed to meet primary endpoints.
Synonyms: IMMUNOGLOBULIN G1, ANTI-(HUMAN IMMUNOGLOBULIN E RECEPTOR TYPE II) (HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .KAPPA.-CHAIN, DIMER, IMMUNOGLOBULIN G1, ANTI-(HUMAN IMMUNOGLOBULIN E RECEPTOR TYPE II) (HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .GAMMA.1-CHAIN), DISULPHIDE WITH HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .KAPPA.-CHAIN, DIMERWashed Microbiota Transplantation
go.drugbank.com/drugs/DB15745InvestigationalThe resulting suspension is shown to decrease FMT-related adverse events. … Fecal microbiota transplantation (FMT) is effective in enhancing the gut microbiota of patients experiencing a high range of disease states, including Clostridioides difficile (C. diff) infection, Crohn
OPC-28326
go.drugbank.com/drugs/DB05461ExperimentalIt is the only clinical compound with this profile. It is currently being investigated in the treatment of peripheral vascular diseases and Raynaud's syndrome. … At low doses, OPC 28326 selectively vasodilates the femoral arterial bed due to its inhibitory action at alpha-2-adrenoceptors while having minimal action on systemic blood pressure, heart rate and coronary
Categories: Heterocyclic Compounds, 1-RingIDM-2
go.drugbank.com/drugs/DB05293ExperimentalIDM-2 is composed of Monocyte-derived Activated Killer (MAK) cells. … IDM produces MAK cells from the patient's own white blood cells by activating these cells ex vivo to allow them to recognize and destroy tumor cells.
Synonyms: IDM-2AGS-004
go.drugbank.com/drugs/DB05742InvestigationalThis approach may overcome the weaknesses of other available therapies and therefore could result in a better chance of success for HIV treatment. … AGS-004 is a personalized RNA-loaded dendritic cellbased immunotherapy that is designed to stimulate the patient’s immune system to target and destroy the patient’s own unique viral burden.
Mitoxantrone
go.drugbank.com/drugs/DB01204ApprovedInvestigationalAn anthracenedione-derived antineoplastic agent.
Synonyms: 1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinoneCategories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index